Related Experiment Video
Updated: Nov 24, 2025
06:21
Adaptable Angled Stereotactic Approach for Versatile Neuroscience Techniques
Published on: May 7, 2020
5.5K
Why target brain adenosine receptors? A historical perspective
Bertil B Fredholm1, Per Svenningsson2
1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Parkinsonism & Related Disorders
|December 22, 2020
Summary
Researchers explored adenosine
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) treatments primarily target dopamine.
- A non-dopaminergic approach offers a novel therapeutic strategy for PD.
Purpose of the Study:
- To investigate adenosine as a non-dopaminergic target for Parkinson's disease.
- To highlight the role of adenosine A2A receptors in basal ganglia circuitry.
Main Methods:
- Review of 50 years of research on adenosine signaling.
- Focus on adenosine A2A receptor localization and function.
Main Results:
- Adenosine is a critical signaling molecule.
- Adenosine A2A receptors are selectively located in the basal ganglia's indirect output pathway.
Conclusions:
- Adenosine A2A receptors present a targeted, non-dopaminergic therapeutic target for Parkinson's disease.
- Modulating these receptors can impact basal ganglia output, offering a new treatment avenue.
More Related Videos
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
4.1K
04:43Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
Published on: June 16, 2023
1.3K
Related Concept Videos
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.3K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.3K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.4K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.4K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.4K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.9K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.9K
01:31Adrenergic Receptors: ɑ Subtype
2.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.4K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.6K